All In Biotech

NDA 022253 · Ucb INC

Vimpat

Lacosamide · Oral

Novel

Last checked: Nov 19, 2026Latest source record: Oct 16, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Oct 28, 2008

Approved uses

9

Original approval plus efficacy supplements

Registered trials

96

41 Phase 3, 6 recruiting

FAERS reports

37,919

29,864 serious, 3,199 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 12, 2026.

VIMPAT is indicated for: Treatment of partial-onset seizures in patients 1 month of age and older ( 1.1 ) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older ( 1.2 ) 1.1 Partial-Onset Seizures VIMPAT is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. 1.2 Primary Generalized Tonic-Clonic Seizures VIMPAT is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.

Mechanism: The precise mechanism by which VIMPAT exerts its antiepileptic effects in humans remains to be fully elucidated. In vitro electrophysiological studies have shown that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • VIMPAT · LACOSAMIDE 200MG · TABLET, ORAL · Prescription · TE AB
  • VIMPAT · LACOSAMIDE 100MG · TABLET, ORAL · Prescription · TE AB
  • VIMPAT · LACOSAMIDE 150MG · TABLET, ORAL · Prescription · TE AB
  • VIMPAT · LACOSAMIDE 50MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Lacosamide" as an intervention, any sponsor and status, largest first.

All 96 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • seizure6,979
  • drug ineffective4,243
  • off label use4,083
  • dizziness1,693
  • somnolence1,521
  • fatigue1,474
  • epilepsy1,466
  • fall1,436
  • overdose1,308
  • status epilepticus1,291
  • generalised tonic-clonic seizure1,209
  • death1,095

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20071
20082
2009332
2010611
2011886
2012875
2013929
2014956
20151,994
20161,342
20171,652
20182,469
20193,766
20202,936
20213,545
20223,208
20233,140
20243,497
20253,315
20262,463

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vimpat* (Lacosamide)

2024 spending

$64.6M

Beneficiaries

6,275

44,046 claims

Per beneficiary

$10,290

$17.18 per unit

View as table
YearSpending
2020$709,365,915
2021$788,463,467
2022$409,943,814
2023$95,150,781
2024$64,570,166

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 192 on PubMed

Sponsor: UCB

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.